Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry.

ABSTRACT:

Background

Metastatic prostate cancer has a 30% 5-year survival rate despite recent therapeutic advances. There is a need to improve the clinical understanding and treatment of this disease, particularly in the real-world setting and among patients who are under-represented in clinical trials.

Objective

We aimed to evaluate the characteristics and clinical outcomes of patients who received their first treatment for metastatic castration-resistant prostate cancer (mCRPC) in routine clinical practice, independent of treatment used, including subgroups with baseline cardiac disease, diabetes mellitus, or visceral metastases.

Patients and methods

Prospective, noninterventional analysis of patient record data in the multicenter Prostate Cancer Registry (PCR) of men with mC

SUBMITTER: Chowdhury S 

PROVIDER: S-EPMC7283204 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature